Massachusetts Financial Services Co. MA Has $45.69 Million Holdings in Certara, Inc. (NASDAQ:CERT)

Massachusetts Financial Services Co. MA lifted its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 40.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,901,898 shares of the company's stock after buying an additional 1,128,006 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 2.42% of Certara worth $45,691,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CERT. Landscape Capital Management L.L.C. bought a new stake in Certara in the 3rd quarter valued at about $852,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Certara during the 3rd quarter worth about $1,513,000. Quest Partners LLC bought a new stake in shares of Certara during the 3rd quarter worth about $367,000. Zions Bancorporation N.A. raised its position in shares of Certara by 18.5% during the 3rd quarter. Zions Bancorporation N.A. now owns 76,811 shares of the company's stock worth $899,000 after buying an additional 11,995 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after buying an additional 1,584 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 7th. Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research report on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Certara presently has a consensus rating of "Hold" and a consensus target price of $15.92.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company's stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company's stock.

Certara Trading Up 7.1 %

Shares of CERT stock traded up $0.74 during trading hours on Monday, reaching $11.10. 857,543 shares of the stock traded hands, compared to its average volume of 798,858. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87. The business has a fifty day moving average price of $10.79 and a 200 day moving average price of $13.17. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.79 billion, a PE ratio of -56.30, a PEG ratio of 5.24 and a beta of 1.51.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 EPS. On average, equities research analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.